Funding Opportunities
|
CALL 2022 Closed Our 7th national investigator-led call for proposals is now closed for applications. We thank the 15 chief investigators and their teams that have submitted an application to this call. The selection process has started, and applicants will hear from us before the end of the year. CALL BeNeFIT-3 will open soon The third BeNeFIT call, in collaboration with ZonMw, will open soon. Research teams from Belgium and the Netherlands will be able to submit an application. |
Progress in funded studies
We are happy to announce the following important milestones have been reached in the trials listed below:
| PRIORI Contract signed |
|
The PRIORI study will recruit pregnant patients with a history of preterm birth in their first trimester of pregnancy to start with synbiotics or placebo. The study will investigate the effect of synbiotics on the vaginal flora and on the pregnancy duration. The chief investigator is Dr Van Holsbeke from ZOL. 402 participants will be recruited from 12 hospitals. |
| BONANZA Contract signed |
The BONANZA trial is testing whether a management strategy guided by early brain tissue oxygen monitoring in patients with severe traumatic brain injury improves long term neurological and functional outcomes. This is an international study, coordinated in Belgium by Pr Dr. Taccone from Erasme Hospital. 220 patients will be included in 11 sites in Belgium. |
|
| SOPRANO CTIS approved |
The SOPRANO trial compares two strategies to administer biological treatments to prevent postoperative endoscopic disease recurrence in Crohn's disease. The chief investigator is Prof. Dr. Ferrante from UZ Leuven. 352 participants will be included in this study across 24 sites. |
|
| Best Cornea FPI |
The Best Cornea trial compares the transplantation of 2 different types of cornea graft, both commonly used, to determine which is the best corneal transplant technique. The DSAEK graft (the standard of care) and the extremely thin DMEK graft (the most recent development). The chief investigator is Prof. Dr. Sorcha Ní Dhubhghaill (UZA). |
|
| DAWN antivirals Study stopped |
The DAWN antivirals trial, testing the efficacy of camostat and molnupiravir for COVID-19 infections presenting to ambulatory care, has been stopped in July 2022 due to poor recruitment. 44 patients have been recruited, during one year, of the 474 foreseen. All sites will be closed. A process evaluation to identify lessons learnt from this study with an innovative organisation will follow. |
The KCE Trials complete portfolio comprises 43 studies. more info>>
Impact
The latest scientific publications are presented below, and links to all publications can be found on the last tab of our dynamic dashboards.
More than 22 000 patients have been recruited so far in KCE funded trials !
Check our dynamic dashboard for real-time recruitment data for all KCE Trials funded studies
More info
